149 related articles for article (PubMed ID: 26696392)
21. Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial.
Gomes Freitas C; Walsh M; Coutinho EL; Vincenzo de Paola AA; Atallah ÁN
PLoS One; 2021; 16(4):e0248567. PubMed ID: 33793580
[TBL] [Abstract][Full Text] [Related]
22. Evaluating warfarin management by pharmacists in a community teaching hospital.
Chilipko AA; Norwood DK
Consult Pharm; 2014 Feb; 29(2):95-103. PubMed ID: 24513419
[TBL] [Abstract][Full Text] [Related]
23. Hemorrhagic events lead to an increase in international normalized ratio in patients on warfarin.
Perona S; Ford M; Rindone J
J Pharm Pract; 2011 Oct; 24(5):494-7. PubMed ID: 22156711
[TBL] [Abstract][Full Text] [Related]
24. Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.
Yanik MV; Irvin MR; Beasley TM; Jacobson PA; Julian BA; Limdi NA
Pharmacotherapy; 2017 Nov; 37(11):1366-1373. PubMed ID: 28949423
[TBL] [Abstract][Full Text] [Related]
25. Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department.
Anthony CJ; Karim S; Ackroyd-Stolarz S; Fry A; Murphy NG; Christie R; Zed PJ
Ann Pharmacother; 2011 Jul; 45(7-8):881-7. PubMed ID: 21750309
[TBL] [Abstract][Full Text] [Related]
26. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure.
Li HK; Chen FC; Rea RF; Asirvatham SJ; Powell BD; Friedman PA; Shen WK; Brady PA; Bradley DJ; Lee HC; Hodge DO; Slusser JP; Hayes DL; Cha YM
Pacing Clin Electrophysiol; 2011 Jul; 34(7):868-74. PubMed ID: 21410724
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration.
Wong YM; Quek YN; Tay JC; Chadachan V; Lee HK
J Clin Pharm Ther; 2011 Oct; 36(5):585-91. PubMed ID: 21070296
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program.
Witt DM; Tillman DJ; Evans CM; Plotkin TV; Sadler MA
Pharmacotherapy; 2003 Mar; 23(3):360-8. PubMed ID: 12627935
[TBL] [Abstract][Full Text] [Related]
29. Clinical consequences of generic warfarin substitution: an ecological study.
Paterson JM; Mamdani M; Juurlink DN; Naglie G; Laupacis A; Stukel TA
JAMA; 2006 Oct; 296(16):1969-72. PubMed ID: 17062858
[No Abstract] [Full Text] [Related]
30. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.
Staerk L; Gislason GH; Lip GY; Fosbøl EL; Hansen ML; Lamberts M; Bonde AN; Torp-Pedersen C; Olesen JB
Europace; 2015 Aug; 17(8):1215-22. PubMed ID: 25995392
[TBL] [Abstract][Full Text] [Related]
31. Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study.
Pallisgaard JL; Lindhardt TB; Hansen ML; Schjerning AM; Olesen JB; Staerk L; Torp-Pedersen C; Gislason GH
PLoS One; 2015; 10(10):e0141377. PubMed ID: 26513589
[TBL] [Abstract][Full Text] [Related]
32. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
[TBL] [Abstract][Full Text] [Related]
33. Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry.
Subherwal S; Peterson ED; Chen AY; Roe MT; Washam JB; Gage BF; Bach RG; Bhatt DL; Wiviott SD; Lopes RD; Alexander KP; Wang TY
Circulation; 2012 Mar; 125(11):1414-23. PubMed ID: 22319105
[TBL] [Abstract][Full Text] [Related]
34. Warfarin therapy: evolving strategies in anticoagulation.
Horton JD; Bushwick BM
Am Fam Physician; 1999 Feb; 59(3):635-46. PubMed ID: 10029789
[TBL] [Abstract][Full Text] [Related]
35. Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials.
Pereira JA; Holbrook AM; Dolovich L; Goldsmith C; Thabane L; Douketis JD; Crowther MA; Bates SM; Ginsberg JS
Ann Pharmacother; 2005; 39(7-8):1188-93. PubMed ID: 15914517
[TBL] [Abstract][Full Text] [Related]
36. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
37. Prevalent aetiologies of non-therapeutic warfarin anticoagulation in a network of pharmacist-managed anticoagulation clinics.
Cryder B; Felczak M; Janociak J; Dela Pena L; Allen S; Gutierrez P
J Clin Pharm Ther; 2011 Feb; 36(1):64-70. PubMed ID: 21198721
[TBL] [Abstract][Full Text] [Related]
38. Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series.
Schultz KT; Bungard TJ
Pharmacotherapy; 2011 Aug; 31(8):793-805. PubMed ID: 21923606
[TBL] [Abstract][Full Text] [Related]
39. Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.
Guidoni CM; Obreli-Neto PR; Pereira LR
J Thromb Thrombolysis; 2014 May; 37(4):542-8. PubMed ID: 24264960
[TBL] [Abstract][Full Text] [Related]
40. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
